LAS VEGAS, Feb. 26, 2016 /PRNewswire/ -- DigiPath, Inc. (OTCQB: DIGP), an independent cannabis testing and media firm, was recently featured in a Bank of America investment report titled Medical Cannabis Has High POTential: A Joint Biotech & Tools Primer.
In the report, Bank of America analysts single out cannabis testing as an area likely to experience enormous growth within the industry. The report suggests that cannabis testing could reach $800 to $900 million in size by 2020, as the $2.9 billion medical cannabis industry appears poised to at least double. Cannabis testing services and lab equipment should experience heightened demand as the industry matures.
DigiPath Labs, a leading cannabis testing facility in Nevada, foresaw the growth in demand for cannabis testing and the tightening of regulations on testing methods and equipment and is positioned to capitalize on the growing market.
Read the entire press release: http://www.cannabisfn.com/bank-of-america-report-is-bullish-on-cannabis-testing/
To learn more about DigiPath Labs, visit www.digipathlabs.com.
About DigiPath, Inc.
DigiPath, Inc., supports the cannabis industry's best practices for reliable testing, education, and training, and brings unbiased cannabis news coverage to the nation. DigiPath's two business units are DigiPath Labs and TNM News Corp.
For more information, go to www.digipath.com.
Information about Forward-Looking Statements
This press release contains "forward-looking statements" that include information relating to future events, and future financial and operating performance. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to: the Company's need for additional funding, the demand for the Company's products, governmental regulation of the cannabis industry, the introduction of new products, the Company's ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company's liquidity and financial strength to support its growth, and other information that may be detailed from time-to-time in the Company's filings with the United States Securities and Exchange Commission. For a more detailed description of the risk factors and uncertainties affecting DigiPath, please refer to the Company's recent Securities and Exchange Commission filings, which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Media Contact: DigiPath Labs, Inc. firstname.lastname@example.org, 702-470-2249
SOURCE DigiPath, Inc.